Veravas

VERAVAS, Inc. is a clinical diagnostics company founded in 2017 and headquartered in Austin, Texas. The company develops diagnostic technologies designed to improve the detection of disease-related biomarkers. Its proprietary VeraBIND™ sample-transformation platform is designed to make difficult biological samples more suitable for measurement, supporting the development of assays for clinical and research applications.

A key product is VeraBIND Tau, a blood-based assay designed to measure the pathological activity of hyperphosphorylated tau, a protein associated with Alzheimer’s disease. The company works with scientific and clinical collaborators to evaluate its technology and advance diagnostic development. Its leadership combines experience in healthcare commercialization, scientific innovation, business growth, and operations. The assay’s clinical use and performance should be understood in line with the evidence and applicable diagnostic guidance.